This year

novo nordisk is winding down victoza across europe while generics hit u.s. shelves

Novo Nordisk confirmed through a series of regulatory notices that Victoza — the 6 mg/mL liraglutide pen that launched the GLP-1 conversation in the U.S. in 2010 — is being withdrawn from European and international markets, with all EU/EEA member states completing the discontinuation by December 2026. Italy's last available date was June 2026. Ireland's was December 2025. The UK pulled Victoza pens from shelves in 2024. Canada lists a discontinuation date of January 2027. Novo Nordisk's notices, logged with multiple national regulators, attribute the withdrawal to commercial reasons rather than safety or quality concerns. The [Pharmaceutical Journal's coverage of Victoza's exit from the UK market](https://pharmaceutical-journal.com/article/news/manufacturer-confirms-discontinuation-of-type-2-diabetes-mellitus-treatment-victoza) in October 2024 documented the moment the brand began its global wind-down. What is filling that shelf space in the U.S.: generic liraglutide. The FDA approved Teva's authorized generic of Victoza in June 2024, Meitheal's generic for type 2 diabetes in April 2025, Teva's generic Saxenda for weight management in August 2025, and Biocon's gSaxenda in February 2026. The molecule is not going anywhere. The brand it launched in is.

The molecule

liraglutide mimics the gut hormone the body degrades in two minutes

Liraglutide is a synthetic analog of glucagon-like peptide-1, the incretin hormone secreted by intestinal L-cells in response to food. Native GLP-1 has a half-life of roughly two minutes in circulation — the enzyme DPP-4 degrades it almost immediately after it is released. Liraglutide extends that window to approximately 13 hours through two structural changes: a single amino acid substitution at position 34 (arginine replaced by lysine) and attachment of a C16 fatty acid chain that binds the peptide to plasma albumin. Albumin turns over slowly, so the bound liraglutide circulates long enough to work as a once-daily injection. When it reaches pancreatic beta cells, it activates the GLP-1 receptor and amplifies insulin secretion in a glucose-dependent way — insulin release is dampened when blood sugar is already low, which is why GLP-1 agonists carry lower hypoglycemia risk than older diabetes drugs. When it reaches GLP-1 receptors in the hypothalamus and brainstem, it modulates the satiety signal that tells the brain food intake has happened. The same mechanism reaching two tissue targets at once is the design logic behind the entire GLP-1 drug class. [PubMed's liraglutide literature](https://pubmed.ncbi.nlm.nih.gov/?term=liraglutide) traces the pharmacology from the original incretin biology to the current clinical programs.

The pitch

the market moved to semaglutide — the question left behind is whether the original still matters

In October 2026, the cultural story on liraglutide is largely about contrast. Semaglutide became the household name — Ozempic and Wegovy dominated the media, the telehealth boom, the shortage, and the compounding legal battle. Tirzepatide arrived with superior weight-loss trial numbers and a dual mechanism story. Liraglutide got recategorized as the older, once-daily, less effective GLP-1 that predated the weekly injection era. That framing has factual support: the SCALE program's pivotal weight-loss trial showed liraglutide achieving roughly 8% average body weight reduction from baseline, compared to semaglutide's approximately 14.9% in the STEP 1 trial. The weight-loss gap is real and documented. What gets lost in the comparison: liraglutide is the drug that ran the first large cardiovascular outcomes trial in the GLP-1 class. It is the one that proved the mechanism was real enough to matter at population scale. The market moving on is not the same as the evidence being wrong. And the generic arrival means liraglutide will now be accessible to patients who could not access the semaglutide price point — which is a different kind of mattering than being the most exciting molecule in the category.

What the data says

the scale and leader trials built the clinical foundation for the glp-1 category

The liraglutide evidence comes in two major programs. The SCALE program covered five randomized controlled trials testing liraglutide 3.0 mg for obesity and overweight with comorbidities — the Saxenda indication. SCALE Obesity and Prediabetes enrolled 3,731 participants; at 56 weeks, the liraglutide arm achieved 8.4% mean body weight reduction from baseline versus 2.8% for placebo. That was the trial data behind the 2014 FDA approval of Saxenda for chronic weight management. The LEAD program covered six trials across type 2 diabetes, establishing the glycemic evidence base for Victoza. But the trial that defined liraglutide's legacy was LEADER: a cardiovascular outcomes trial enrolling 9,340 adults with type 2 diabetes and established cardiovascular disease or high risk, randomized to liraglutide or placebo, followed for a median of 3.8 years. LEADER showed a statistically significant 13% relative risk reduction in the primary composite outcome of cardiovascular death, nonfatal MI, or nonfatal stroke — the first positive cardiovascular outcomes trial in the GLP-1 class. [ClinicalTrials.gov records the SCALE and LEADER programs](https://clinicaltrials.gov/search?term=liraglutide+LEADER+SCALE), and the [DailyMed prescribing information for liraglutide products](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=liraglutide) carries the LEADER finding in its labeled cardiovascular indication language.

Approved — PeptideFactCheck stance

the brand is retiring but the evidence tier does not follow it out the door

Liraglutide holds PeptideFactCheck's Approved evidence tier — the highest classification used here — because FDA approval for specific indications exists, backed by multiple large randomized controlled trials across glycemic control, weight management, and cardiovascular outcomes. Approved means regulatory certainty for labeled uses, not a blank check for every position the internet assigns to the molecule in the hierarchy of GLP-1 drugs. Novo Nordisk's decision to retire the Victoza and Saxenda brands is a portfolio decision. It reflects the commercial reality that once-weekly semaglutide is significantly more convenient and generates better weight-loss outcomes in controlled trials than once-daily liraglutide. It does not change the trial record, and it does not make liraglutide ineffective. The generic arrival is an access story: the molecule works, the evidence is there, the price is coming down. Whether generic liraglutide is the right choice for any given patient is a clinical judgment that belongs with the prescribing physician and the current label. What this October 2026 moment represents, read correctly, is the normalization of a drug class: the original brand ages out, generics carry the molecule forward, and the evidence trail that always was there stays in place. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.